Im Focus Onkologie

, Volume 21, Issue 4, pp 65–66 | Cite as

Sonografie bei Verdacht auf Leberkrebs

Diagnose geht auch ohne Biopsie

Gastroonkologie Fortbildung
  • 6 Downloads

Nicht wenige Patienten in der Hausarztpraxis haben ein erhöhtes Risiko, an einem hepatozellulären Karzinom zu erkranken. Diese sollten identifiziert und halbjährlich per Ultraschall gescreent werden. Dabei ist heutzutage eine sichere Diagnose auch ohne Biopsie möglich — dank kontrastverstärkter Bildgebung.

Literatur

  1. 1.
    Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefGoogle Scholar
  2. 2.
    World Health Organization: World cancer statistics 2012.Google Scholar
  3. 3.
    Bouattour M et al. Recent Developments of c-Met as a Therapeutic Target in Hepatocellular Carcinoma. Hepatology. 2018;67(3):1132–49.CrossRefGoogle Scholar
  4. 4.
    Tanaka Y et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002; 99(24):15584–9.CrossRefGoogle Scholar
  5. 5.
    Cramp ME et al. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol. 2014; 14:137.CrossRefGoogle Scholar
  6. 6.
    Rahman R et al. Primary hepatocellular carcinoma and metabolic syndrome: An update. World J Gastrointest Oncol. 2013;5(9):186–94.CrossRefGoogle Scholar
  7. 7.
    S3-Leitlinie „Hepatozelluläres Karzinom“, AWMF-Registernummer 032/053OL.Google Scholar
  8. 8.
    Claudon M et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultraschall Med. 2013;34(1):11–29.PubMedGoogle Scholar
  9. 9.
    Leoni S et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? Ultraschall Med. 2013;34(3):280–7.CrossRefGoogle Scholar
  10. 10.
    Friedrich-Rust M et al. Contrast-Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a metaanalysis. Liver Int. 2013;33(5):739–55.CrossRefGoogle Scholar
  11. 11.
    Oken M et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.CrossRefGoogle Scholar
  12. 12.
    Greten TF, Manns MP. Hepatocellular carcinoma — diagnosis and treatment. Dtsch Med Wochenschr. 2008;133:1907–10.CrossRefGoogle Scholar
  13. 13.
    Schellhaas B et al. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol. 2017;29(9):1036–44.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik 1ErlangenDeutschland

Personalised recommendations